BCRX
BioCryst Pharmaceuticals, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
9.66
▼ 0.00 (0.00%)
MARKET · —
Price
Open
9.66
Prev close
9.66
Day high
9.91
Day low
9.48
Volume
2.42M
Market cap
$2.44B
P/E (TTM)
—
52W range
6.00 – 11.22
Trailing performance
Returnvs SPY
1W
-1.95%
-0.6%
1M
+1.81%
-1.9%
3M
+14.10%
+11.0%
6M
+28.19%
+17.1%
YTD
+22.44%
+10.1%
1Y
+13.96%
-6.0%
3Y
+38.01%
-36.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$2.44B
Enterprise value$2.92B
Revenue (TTM)$940.61M
Gross profit$727.92M
EBITDA$433.65M
Net income$-384.67M
EPS (TTM)$-1.40
Free cash flow$324.27M
Total cash$352.57M
Total debt$836.64M
Book value / share$-1.78
Shares outstanding255.54M
Float222.36M
Short % of float12.93%
Dividend yield—
Beta (5Y)0.55
Valuation & profitability ratios
Trailing P/E—
Forward P/E10.16
PEG ratio9.39
Price / sales—
Price / book—
EV / revenue3.11
EV / EBITDA6.74
Gross margin77.39%
Operating margin45.12%
Profit margin-40.90%
Return on equity—
Return on assets52.86%
Debt / equity—
Current ratio2.32
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $874.84M | $450.71M | $331.41M | $270.83M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $263.86M | -$88.88M | -$226.54M | -$247.12M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $263.86M | -$88.88M | -$226.54M | -$247.12M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.24 | 0.35 | +49.4% |
| Mar 2026 | 0.11 | 0.14 | +27.7% |
| Dec 2025 | 0.07 | 0.21 | +197.6% |
| Sep 2025 | 0.07 | 0.16 | +125.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.12 | 2 | $165.53M | +3.9% |
| Next quarter | 0.13 | 2 | $169.41M | -58.3% |
| Current year | 0.75 | 2 | $702.23M | -19.7% |
| Next year | 0.94 | 2 | $737.28M | +5.0% |
Analyst targets & ownership
Mean target$20.82
High target$32.00
Low target$12.00
Implied upside115.51%
Analyst count11
ConsensusSTRONG BUY
Strong buy / Buy3 / 7
Hold1
Sell / Strong sell0 / 0
Held by insiders1.20%
Held by institutions105.35%
Institutions holding412
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+646.24K
Net buying
Buy transactions
24
919.86K shares
Sell transactions
4
273.61K shares
Net transactions
+28
Buys less sells
Sell : buy shares
0.3 : 1
Mixed
Insider-held shares
3.05M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 11, 26 | STONEHOUSE JON P Director |
STOCK | 15.29K | $0 | Direct |
| Jun 11, 26 | GALSON STEVEN K Director |
STOCK | 15.29K | $0 | Direct |
| Jun 11, 26 | FRANK STEVEN R Director |
STOCK | 15.29K | $0 | Direct |
| Jun 11, 26 | MILNE JILL C. PH.D. Director |
STOCK | 15.29K | $0 | Direct |
| Jun 11, 26 | SANDERS MACHELLE Director |
STOCK | 15.29K | $0 | Direct |
| Jun 11, 26 | LEVIN ALAN G Director |
STOCK | 15.29K | $0 | Direct |
| Jun 11, 26 | MILANO VINCENT J Director |
STOCK | 15.29K | $0 | Direct |
| Jun 11, 26 | HEGGIE THERESA Director |
STOCK | 15.29K | $0 | Direct |
| Jun 11, 26 | MCKEE AMY E Director |
STOCK | 15.29K | $0 | Direct |
| May 29, 26 | STONEHOUSE JON P Director |
STOCK | 631 | $5.62K | Direct |
| May 29, 26 | FRANK STEVEN R Director |
STOCK | 1.26K | $11.24K | Direct |
| May 29, 26 | MILNE JILL C. PH.D. Director |
STOCK | 1.26K | $11.24K | Direct |
| May 29, 26 | MILANO VINCENT J Director |
STOCK | 1.12K | $10.00K | Direct |
| May 29, 26 | MCKEE AMY E Director |
STOCK | 631 | $5.62K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BARNES ALANE P |
Officer | 400.70K | Conversion of Exercise of derivative security |
DOYLE ANTHONY |
Chief Financial Officer | 377.87K | Stock Award(Grant) |
GALSON STEVEN K |
Director | 86.17K | Stock Award(Grant) |
GAYER CHARLES K |
President | 952.58K | Conversion of Exercise of derivative security |
GHIAS BABAR |
Chief Financial Officer | 268.70K | Stock Award(Grant) |
HUTSON NANCY J |
Director | 99.14K | Stock Award(Grant) |
MENON SANDEEP |
Officer | 205.15K | Stock Award(Grant) |
MILANO VINCENT J |
Director | 108.48K | Stock Award(Grant) |
STONEHOUSE JON P |
Director | 1.42M | Stock Award(Grant) |
THACKRAY HELEN M |
Officer | 384.84K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
9.92
-2.66% from price
SMA 20
9.59
-0.46% from price
SMA 50
9.60
-0.52% from price
SMA 100
9.29
+3.96% from price
SMA 200
8.43
+13.27% from price
EMA 12
9.73
-0.77% from price
EMA 26
9.65
+0.10% from price
EMA 50
9.52
+1.49% from price
RSI (14)
48.6
Neutral
MACD (12,26,9)
0.08
Hist 0.00
ATR (14)
0.53
5.58% of price
Realised vol 30D
48.1%
Annualised
Bollinger upper
10.48
20, 2σ
Bollinger lower
8.71
20, 2σ
50 / 200 cross
Golden
9.60 vs 8.43
Trend bias
Above 200
+13.27%
Risk profile
Beta vs SPY
0.60
Less volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
48.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-27.3%
Peak to trough
Max drawdown 5Y
-79.1%
Peak to trough
ATR 14
0.53
5.58% of price
Beta (reported)
0.55
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.30
Call-heavy session
Put / call open interest
0.17
Positioning, not flow
Max pain
10.00
+4.7% from spot
ATM implied vol
69.9%
Nearest strike to spot
Skew (10% OTM)
-9.2%
Calls bid over puts
Call volume
1.41K
Contracts, this expiry
Put volume
415
Contracts, this expiry
Heaviest call OI
15.00
11.75K contracts
Heaviest put OI
11.00
2.49K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Why Did BioCryst Pharmaceuticals (BCRX) Shares Climb After Its Latest Update?
Simply Wall St. · 9d ago
BioCryst Pharmaceuticals (BCRX) Stock Looks Cheap Even After A 53% Gain
Simply Wall St. · 9d ago
BioCryst (BCRX) Q2 2026 Earnings Call Transcript
Motley Fool · 10d ago
Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
Zacks · 10d ago
Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options
Zacks · 11d ago
A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?
24/7 Wall St. · 11d ago
RBC Adjusts Price Target on BioCryst Pharmaceuticals to $13 From $14, Maintains Outperform Rating
MT Newswires · 16d ago
BioCryst Pharmaceuticals Inc (BCRX) (Q2 2026) Earnings Call Highlights: Record Revenue and ...
GuruFocus.com · 17d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.